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Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic
studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show
increased prevalence in the metastatic, endocrine-resistant setting. No naturally occurring
ESR1 mutations have been reported in in vitro models of BC either before or after the
acquisition of endocrine resistance making functional consequences difﬁcult to study. We
report the ﬁrst discovery of naturally occurring ESR1Y537C and ESR1Y537S mutations in MCF7
and SUM44 ESR1-positive cell lines after acquisition of resistance to long-term-estrogen-
deprivation (LTED) and subsequent resistance to fulvestrant (ICIR). Mutations were enriched
with time, impacted on ESR1 binding to the genome and altered the ESR1 interactome. The
results highlight the importance and functional consequence of these mutations and provide
an important resource for studying endocrine resistance.
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Over 70% of breast cancers (BC) are estrogen receptor-α(ESR1) positive at diagnosis. Estrogen mediates its effectsby binding to ESR1 leading to expression of genes con-
trolling proliferation and cell survival. ESR1 has two distinct
activation domains, AF-1 and AF-2. AF-1 is regulated by phos-
phorylation while AF-2 is integral to the ligand-binding domain
(LBD) and associates with coactivators, controlling the ESR1
transcriptional complex (reviewed by Green and Carroll1). Clas-
sically, patients with ESR1-positive BC are treated with endocrine
agents such as tamoxifen, aromatase inhibitors (AIs), or fulves-
trant, which impede ESR1-signaling (reviewed by Ma et al.2).
Although over 50% of ESR1-positive patients show response to
endocrine therapy and estrogen deprivation therapy reduces BC
mortality by 40%3, a large proportion relapse with de novo or
acquired resistant disease, making it one of the greatest challenges
for BC research and treatment.
Multiple mechanisms of resistance have been proposed, most
of which have been identiﬁed using a limited number of ESR1-
positive BC cell lines. These include aberrant cross-talk between
ESR1 and growth factor signaling pathways or alterations in the
balance of coactivators and corepressors (reviewed by Ma et al.2,
Osborne et al.4, and Miller et al.5).
It has been known for many years that some mutations in ESR1
can lead to ligand-independent activation, but until recently, such
mutations appeared to have little clinical signiﬁcance6, as their
presence in primary disease is rare. However, the prevalence of
ESR1 mutations in metastatic tumors that have recurred or
progressed after endocrine therapy is far higher7–9. We have
recently reported that the detection of these mutations in circu-
lating tumor DNA (ctDNA) of 39.1% of metastatic patients
appears to correlate with clinical resistance to AIs10. The majority
of ESR1 mutations are located at two amino acids in the LBD
Y537N/C/S and D538G. Functional studies using ectopic
expression of these mutations led to constitutive activity of ESR1
and conferred partial resistance to established clinical doses of
tamoxifen and fulvestrant11,12. However, as these mutations were
engineered, the role of cellular context during acquisition of
resistance with time was not explored.
In this manuscript, we report for the ﬁrst time, the identiﬁ-
cation of naturally occurring ESR1 mutations in BC cell models
and their enrichment during acquisition of resistance to endo-
crine therapy. We show that the mutated ESR1 controls a cis-
trome similar to the ligand-dependent wt ESR1 and associates
with an altered protein interactome enabling ligand-independent
proliferation. Furthermore, these naturally occurring ESR1
mutants are sensitive to fulvestrant, suggesting that this and
similar agents may have applicability in patients with tumors
harboring these mutations supporting our recent clinical data13.
Results
Discovery of ESR1 mutations in models of endocrine resis-
tance. Previously, we reported the development of long-term-
estrogen-deprived (LTED) derivatives from a number of ESR1-
positive BC cell lines (including MCF7, HCC1428, T47D, ZR75.1,
and SUM44)14,15. In general, estrogen deprivation leads to an
initial quiescent population accompanied by cell death and after
many weeks to outgrowth of a cell population that then pro-
liferates independently of exogenous estrogen (Supplementary
Fig. 1a–d). The phenotype of the LTED cell lines varies leading to
a context-speciﬁc sensitivity or resistance to additional agents14.
As ESR1 mutations have been associated with resistance to
endocrine therapy, we explored whether these mutations or those
of other genes were either enriched or acquired in the in vitro
models described. Whole-exome sequencing from wt-MCF7 and
MCF7-LTED showed an ESR1Y537C mutation in the MCF7-
LTED at an estimated variant allele frequency (VAF) of 30%,
while it was undetectable in the wt-MCF7. The mutation was
validated using digital droplet (dd) PCR (Fig. 1a, b).
ESR1 mutations occur in LTED but not tamoxifen-resistant
cells. As a result of this unexpected ﬁnding, we sequenced known
hotspot regions for ESR116 by Ion Torrent in wt and LTED
derivatives of MCF7, SUM44, HCC1428, and ZR75.1, together
with tamoxifen-resistant (TAMR) derivatives of MCF7 and
HCC1428 and fulvestrant-resistant (ICIR) derivatives of wt-
MCF7, MCF7-LTED, and ZR75.1-LTED (Table 1; Supplementary
Fig. 2). The ESR1Y537C mutant was detected in the MCF7-LTED-
ICIR cells at a VAF of 48% that was conﬁrmed by ddPCR (49.8%)
(Supplementary Fig. 3a) but was not detected in the wt-MCF7-
ICIR cells. Comparison of the two isogenic models showed that
fulvestrant resistance (Supplementary Fig. 3b) occurred irre-
spective of the mutation. Furthermore, both ICIR derivatives
showed a marked reduction in ESR1 (Supplementary Fig. 3c) and
a concomitant drop in expression of estrogen-regulated genes
(GREB1, PDZK1, PGR, and TFF1) but equivalent expression of
genes associated with proliferation when compared to their
respective wt (Supplementary Fig. 3d).
Strikingly, analysis by Ion torrent also revealed an ESR1Y537S
heterozygous mutation in SUM44-LTED (VAF 47%). ESR1
mutations were conﬁrmed by Sanger sequencing, RNA sequen-
cing, mass spectrometry, and whole-exome sequencing (Supple-
mentary Fig. 4a–g). Exome sequencing did not reveal any
additional mutated genes involved in AI resistance beyond the
mutation in ESR1 nor did it reveal mutations in genes known to
be drivers of BC17 that might promote growth by other
mechanisms (Supplementary Data 1).
In order to determine if the ESR1Y537C VAF of 30% in the
MCF7-LTED cells was indicative of a mixed population of cells
harboring either ESR1wt or ESR1Y537C, we assessed ESR1 copy
number by ﬂuorescent in situ hybridization (FISH) and exome
sequencing. This revealed an allelic imbalance, which on average
identiﬁed two or more wt copies of ESR1 and one mutant copy
per cell in the MCF7-LTED, indicating 100% of the cell
population harbored the mutation. In contrast, the MCF7-
LTED-ICIR cells were enriched for two copies of ESR1 per cell
similar to the SUM44-LTED, accounting for the VAF of 50%
again indicating every cell in the given population contained a
mutation (Supplementary Fig. 5).
Temporal enrichment of ESR1 mutations during estrogen
deprivation. Analysis by ddPCR over a time course showed that
the ESR1Y537S mutation was detectable within 12 weeks following
transfer of SUM44 cells to estrogen-free medium (Fig. 1c).
Thereafter, the VAF increased progressively up to 50%. In order
to determine if the mutation was present in the parental popu-
lation or was acquired as a result of the selective pressure of
estrogen withdrawal, we screened over 6 × 106 matched parental
SUM44 copies. Interestingly, the ESR1Y537S mutation was present
in wt-SUM44 at an apparent frequency of ~1:1.000.000 (Fig. 1d),
implying that the ESR1Y537S mutation pre-exists in a very small
proportion of SUM44 cells. We further screened a second batch
of SUM44-LTED and their corresponding parent cell line18 but
no mutation was identiﬁed, suggesting this is not the only
adaptive mechanism. In order to control further the potential of
contamination, we screened an equivalent number of ESR1-
negative SKBR3 cells and no mutation was evident (Fig. 1d).
Finally, to address the possibility that the Y537C mutation was
also resident at low frequency in MCF7 cells, we screened three
independent batches, covering over 6 × 106 copies, however we
were unable to identify the Y537C mutation.
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Fig. 1 Identiﬁcation and characterization of ESR1 mutations in models of endocrine resistance. a Visualization of ESR1Y537C identiﬁed during exome
sequencing. b Digital droplet PCR (ddPCR) showing the presence of the ESR1Y537C mutation in MCF7-LTED. c ddPCR showing the presence of the ESR1Y537S
mutation in SUM44-LTED. Temporal analysis showing enrichment of the mutation from wk12 post-estrogen deprivation. d ddPCR showing the presence of
ESR1Y537S at low variant allele frequency (VAF) in wt-SUM44 but not in SKBR3. e Overlap between wt-SUM44 and SUM44-LTED ESR1 binding sites and
corresponding heatmap. The heatmap depicts binding peak intensities, which are common or different between the two cell lines. The window represents
±5 kb regions from the center of the binding event. f Comparison of the average read count between wt-SUM44 and SUM44-LTED showing peak afﬁnity
for the common and different binding events between the two cell lines. g Motif analysis of common and augmented ESR1 peaks from wt-SUM44 vs.
SUM44-LTED. p-value of “common peaks” based on average of three random selections of 2150 peaks to approximately match the number of peaks within
the “augmented peak” comparisons. h GSEA was conducted comparing RNA-seq with ESR1-induced binding events in SUM44-LTED. ChIP-seq analysis
was carried out using data from two biological replicates and RNA-seq from three biological replicates
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01864-y ARTICLE
NATURE COMMUNICATIONS |8:  1865 |DOI: 10.1038/s41467-017-01864-y |www.nature.com/naturecommunications 3
ESR1Y537S drives ligand-independent transcription. To deter-
mine the function of ESR1Y537S, we performed ChIP-seq with
antibodies for ESR1 in asynchronous wt-SUM44 in the presence
of estrogen and SUM44-LTED in the absence of estrogen.
Overlap of two replicate experiments called 28,647 and 23,294
ESR1 binding events in wt-SUM44 and SUM44-LTED cells,
respectively. The vast majority (80%) of the ESR1Y537S binding
sites in SUM44-LTED cells were common to ESR1wt binding sites
in estrogen-treated wt-SUM44 (Fig. 1e). Although 4702 differ-
ential binding sites were called in the SUM44-LTED cells, these
were not unique, but represented enriched ESR1 binding, i.e., they
also appeared in wt-SUM44 and this was similarly the case for the
10,055 differential binding sites in wt-SUM44 that occurred in the
SUM44-LTED but were not enriched to the same level (Fig. 1f).
Peak strength was evaluated at a number of target genes
(Supplementary Fig. 6a), where augmented ESR1Y537S binding
was evident in SUM44-LTED compared to wt-SUM44. Further-
more, ChIP-qPCR validation assessing recruitment of ESR1Y537S
together with FOXA1, a major pioneer factor for ESR119 and CBP
required for an authentic ESR1 transcriptional complex20,
showed enhanced binding to the promoters of TFF1 and GREB1
in the SUM44-LTED compared to wt cell line (Supplementary
Fig. 6b).
ESR1 binding sites in both cell lines showed a similar pattern of
genomic distribution (Supplementary Fig. 6c). Furthermore, the
vast majority of binding motifs were similar for ESR1wt and
ESR1Y537S, however, signiﬁcant enrichment for motifs represent-
ing the transcription factors ESR1, RARA, PAX2, ANDR, and
FOXA1 were evident in relation to the enriched ESR1 peaks
found in SUM44-LTED, compared to wt-SUM44, which
conversely showed increased GATA3 (Fig. 1g).
To identify the transcription targets of ESR1Y537S, we
integrated ChIP-seq and RNA-seq data from the respective cell
lines. Gene set enrichment analysis (GSEA) showed that
increased ESR1Y537S genomic binding correlated with increased
transcription, whereas loss of binding correlated with down-
regulation of genes in SUM44-LTED (Fig. 1h; Supplementary
Fig. 6d). We next used K-means clustering to compare the ESR1
binding patterns with expression of genes in wt-SUM44, wt-
SUM44 after 1 week of estrogen deprivation and the SUM44-
LTED (20 weeks of estrogen deprivation). We identiﬁed four
distinct gene sets17 (Fig. 2a–c): GS1 consisted of classical
estrogen-regulated genes such as TFF1, GREB1, PGR, and
CCND1, which decreased in expression after 1 week of
deprivation but were elevated in the SUM44-LTED. GS4
contained genes such as FOXA1 that were enriched after the
ﬁrst week of estrogen deprivation and remained active in the
LTED. GS2 and 3 included genes, such as MYC and JUN, which
were downregulated in the SUM44-LTED compared to wt-
SUM44. Pathway analysis of the four clusters showed enrichment
of ESR1 signaling, epithelial-to-mesenchymal transition (EMT),
mTORC1 complex activation, and cholesterol homeostasis in the
SUM44-LTED.
To address this further, we assessed the metabolic capability of
the wt-SUM44 and SUM44-LTED using Seahorse (Fig. 2d). No
signiﬁcant change in glutamine dependency was evident between
the two cell lines; however, the SUM44-LTED showed a
signiﬁcantly higher glutamine capacity and fatty acid dependency
compared to the wt-SUM44. The SUM44-LTED also showed a
slight but signiﬁcant decrease in glucose dependency.
Finally, we assessed the migratory ability of the cell lines
(Fig. 2e). The SUM44-LTED showed a two-fold increase (p<
0.001, Student’s t test) in migration compared to wt-SUM44.
Collectively, these ﬁndings suggest that ESR1Y537S mediates
binding events that are functionally signiﬁcant and lead to
expression of genes controlling proliferation, survival and EMT,
in a ligand-independent manner and while many ESR1 binding
events are similar between the two lines, differences do exist and
are probably the result of, or inﬂuenced by, the cellular context.
ESR1Y537S interacts with known ESR1 binding proteins. In
order to elucidate the impact of the Y537S mutation on the ESR1
interactome and proteome, we carried out comparative RIME
(rapid immunoprecipitation with tandem mass spectrometry of
endogenous proteins) and dimethyl labeling21 between wt-
SUM44 and SUM44-LTED (Fig. 3a; Supplementary Fig. 7a, b).
RIME demonstrated ESR1Y537S associated with a similar portfolio
of proteins to those seen for ESR1wt including ESR1 itself, as well
as, PGR, TLE3, HAT1, and FOXA122. However, increased asso-
ciation between ESR1Y537S GREB1 and FOXA1 was noted, which
we conﬁrmed by Co-IP (Supplementary Fig. 7c). Quantitation of
proteins by dimethyl labeling showed increased abundance of
TFF1 and a slight increase in ESR1 but not FOXA1 (Supple-
mentary Fig. 7d).
Immunoblot analysis of wt-SUM44 and SUM44-LTED under
basal growth conditions was assessed for changes in growth factor
receptors and down stream pathways associated with endocrine
resistance2 as well as alterations in pESR1ser118, pESR1ser167, and
PGR (Fig. 3b; Supplementary Fig. 8). No signiﬁcant changes in
pEGFR or pERBB2 were apparent between the cell lines. A slight
increase in pERK1/2 was seen in SUM44-LTED but no change in
pAKTser473. The level of pESR1ser118 was greater in wt-SUM44
compared to the SUM44-LTED. However, a slight increase in
Table 1 Identiﬁcation of naturally occurring ESR1 mutations in cell line models of endocrine sensitive and resistant breast cancer
Cell line No. of batches screened No. of positive batches Mutation VAF (%)
wt-MCF7 4 0 – –
MCF7-LTED 4 1 Y537C 30
MCF7-TAMR 1 0 – –
wt-MCF7-ICIR 1 0 – –
MCF7-LTED-ICIR 1 1 Y537C 50
wt-HCC1428 1 0 – –
HCC1428-LTED 1 0 – –
HCC1428-TAMR 1 0 – –
wt-SUM44 2* 1 Y537S 0.0001
SUM44-LTED 2* 1 Y537S 50
wt-ZR75.1 1 0 – –
ZR75.1-LTED 1 0 – –
*Second batch originated from an independent laboratory
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pESR1ser167 was noted in the LTED model (Fig. 3b). To address
this further, both wt-SUM44 and SUM44-LTED were cultured in
DCC medium in the absence or presence of estrogen. In this
setting, ESR1 abundance and phosphorylation proﬁles were
similar between the SUM44-LTED in the absence of estrogen and
the wt-SUM44 in the presence of estrogen. Overall, these data
showed the proﬁle of the wt-SUM44 and SUM44-LTED were
similar (Supplementary Fig. 7e).
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As FOXA1 is an important pioneer factor regulating ESR1-
driven transcription23, and FOXA1 sites were enriched in our
ChIP-seq analysis of SUM44-LTED cells, we hypothesized that it
played a pivotal role in transcriptional regulation of ESR1Y537S.
Small interfering RNA (siRNA) knockdown of
FOXA1 signiﬁcantly reduced proliferation of both wt-SUM44
(42%, p< 0.001, Student’s t test) and SUM44-LTED cells
although this was more pronounced in the latter (75%, p<
0.001, Student’s t test) (Fig. 3c). siFOXA1 also correlated with a
signiﬁcant reduction in the expression of TFF1 and CCND1
(Fig. 3d), suggesting FOXA1 plays a crucial role in the ligand-
independent transcriptional activity of ESR1Y537S.
CRISPR analysis shows ESR1Y537S controls ligand indepen-
dence. As kinase signaling has been strongly implicated in
endocrine resistance resulting in ligand-independent activity of
ESR12, we sought an approach that would reduce the effect of this
confounding inﬂuence. In this setting, wt-MCF7, which harbor
ESR1wt, were engineered to introduce the ESR1Y537S mutation
using CRISPR-Cas9 genome editing. MCF7Y537S cells carry one
endogenous ESR1 gene in which, ESR1wt has been mutated to
code for the ESR1Y537S mutation, as well as ESR1wt. Detailed
functional analyses of MCF7Y537S cells are described elsewhere24.
Proliferation assays in the absence of exogenous estrogen showed
the MCF7Y537S was ligand-independent (Fig. 4a). Furthermore,
levels of ESR1 expression between the wt and the mutated cell line
were similar (Fig. 4b; Supplementary Fig. 8). Analysis of ESR1
ChIP-seq from wt-MCF7 and MCF7Y537S in the absence
of exogenous estrogen showed 3602 common peaks across
the genome and 8094 unique binding events in MCF7Y537S
(Fig. 4c, d). Furthermore, peak afﬁnity was greater for ESR1Y537S
across the genome while binding events were similarly distributed
for both ESR1wt and ESR1Y537S (Fig. 4e, f). Overlay of the binding
events from ChIP-seq analysis with corresponding RNA-seq from
MCF7Y537S showed increased expression of proliferation-
associated genes and known estrogen-regulated genes, which
was conﬁrmed by protein expression (Fig. 4b, g; Supplementary
Fig. 8). This data suggest the mutation alone is sufﬁcient to hold
ESR1 in a conformation suitable for recruitment of coactivators
together with the basal transcription machinery and that these
mutations may not require altered kinase proﬁles to be active. Of
note, treatment of both cell lines with estrogen revealed 74%
concordance in ESR1 binding events suggesting ESR1Y537S
remained responsive to ligand (Fig. 4h).
Intersect of the ESR1 binding events in SUM44-LTEDY537S and
MCF7Y537S (Fig. 4h) showed over 50% of the peaks called
in MCF7Y537S were common to those in SUM44-LTEDY537S.
Overlay of the common binding events with RNA-seq showed
enrichment of genes associated with Hallmark pathways such as
early (p-value = 10−72, hypergeometric test) and late (p-value = 10−43,
hypergeometric test) estrogen responsiveness, EMT transition
(p-value = 10−18, hypergeometric test), mTORC1 signaling
(p-value = 10−12, hypergeometric test), and fatty acid metabolism
(p-value = 10−9, hypergeometric test) (Supplementary Data 2).
Nonetheless, differences between the cell lines highlight the inﬂuence
of phenotypic nuances on the ESR1 function.
ESR1wt and ESR1Y537C have altered genome-wide binding
patterns. Two MCF7-LTED derivatives were sequenced, of which
one harbored an ESR1Y537C (MCF7-LTEDY537C) and the other
ESR1wt (MCF7-LTEDwt) (as conﬁrmed by ddPCR Supplementary
Fig. 9a), suggesting LTED itself may not always select for muta-
tions. Indeed, there are no previous reports of ESR1 mutations in
LTED cells. Further interrogation of the whole-exome sequencing
data from both MCF7-LTED models showed an increased
mutational load in the MCF7-LTEDY537C compared to the
MCF7-LTEDwt. However, no high impact mutations previously
associated with AI resistance2 were evident in either cell line other
than ESR1Y537C (Supplementary Data 1). Immunoblotting
showed that while key signaling pathways appeared similar
between the LTED derivatives, expression of PGR differed sig-
niﬁcantly (Supplementary Fig. 9b). We therefore hypothesized
that the mutant ESR1Y537C and ESR1wt controlled different ESR1
cistromes. To address this, genome-wide binding of ESR1 was
assessed in both MCF7-LTED derivatives and the corresponding
wt-MCF7. Assessment of the distribution of ESR1 binding
showed increased occupancy at the promoter (<1kb) in MCF7-
LTEDwt (9.2%, p = 10−94 χ2-test) and MCF7-LTEDY537C (28.4%,
p = 0 χ2-test) compared to wt-MCF7 (3.3%). The converse was
observed for the distal intergenic regions (Fig. 5a). To address this
further, we used DiffBind and identiﬁed 4744 differential binding
events between the MCF7-LTEDwt and wt-MCF7, 13,824
between MCF7-LTEDY537C and wt-MCF7, and 11,018 between
MCF7-LTEDwt and MCF7-LTEDY537C (FDR< 5%) (Supple-
mentary Fig. 9c, d). This suggested that the ESR1Y537C and
ESR1wt in the MCF7-LTED cell lines control altered cistromes in
comparison to wt-MCF7, but also differed between each other. Of
interest, both LTED cell lines showed increased expression of
GATA3, CDK1, RET, and ESR1 compared to the parental cell line
(Fig. 5b). However, MCF7-LTEDY537C showed increased
expression of estrogen-regulated genes such as PGR and TFF1
together with AREG, while MCF7-LTEDwt showed increased
expression of BCL2 and XBP1 (Fig. 5b). K-means clustering of the
ChIP-seq and RNA-seq data conﬁrmed that the ESR1Y537C
mutation appeared to function “classically” in the absence of
ligand compared to MCF7-LTEDwt. Noteworthy, both LTED
derivatives enriched for pathways associated with PI3K/AKT/
mTORC compared to wt-MCF7 but differed in the down stream
impact of these pathways when comparing clusters 1 and 3
(Fig. 5c–e).
We next assessed the metabolic capability of the cell lines,
which was similar for both capacity and dependency on
glutamine, and glucose (Fig. 5f). However, the MCF7-LTEDwt
showed higher dependency on fatty acids (p< 0.05, one-way
ANOVA and Tukey’s test).
Finally, and in keeping with the SUM44-LTED, both MCF7-
LTED derivatives were highly migratory compared to wt-MCF7
(Fig. 5g).
In order to further delineate the dependency of the MCF7-
LTEDY537C on the mutant ESR1, we carried out a CRISPR-Cas9
reversion editing Y537C to Y537 (ESR1Δ537C) (Supplementary
Fig. 10a, b). In keeping with our previous data, MCF7-LTEDY537C
showed ligand-independent growth. Contrastingly, MCF7-
Fig. 2 ESR1Y537S controls proliferation, EMT, and altered metabolism in SUM44-LTED. a Heatmap depicting the changes in gene expression from four
identiﬁed clusters of genes that were signiﬁcantly differentially expressed and bound by ESR1wt (wt-SUM44) or ESR1Y537S (SUM44-LTED). b Average log2
differences in ESR1 binding for all genes within each cluster during the course of adaptation to LTED. c Pathway analysis of the four clusters using GSEA.
Sample labels represent: +E wk0=wt-SUM44, −E wk1= 1 wk E-deprived SUM44, −E wk 20= SUM44-LTED. d Metabolic dependency and capacity of wt-
SUM44 and SUM44-LTED on glutamine, fatty acid, and glucose using a Seahorse XFe96 analyzer. (n= 4 technical replicates). e Comparison of the
migratory ability of wt-SUM44 and SUM44-LTED (n= 8 technical replicates). Error bars represent mean± SEM. Signiﬁcance was assessed by Student’s t
test. *p< 0.05, **p< 0.01, ***p< 0.001
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LTEDΔ537C and wt-MCF7 revealed limited proliferation in the
absence of estrogen (Supplementary Fig. 10c). Furthermore,
MCF7-LTEDΔ537C switched to estrogen dependency and
phenocopied the response of wt-MCF7 to fulvestrant (Supple-
mentary Fig. 10d, e). Immunoblotting and RT-qPCR showed that
MCF7-LTEDΔ537C regain estrogen dependency for expression of
FOXA1 TFF1 CCND1
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Fig. 3 Identiﬁcation and functional analysis of the ESR1Y537S interactome. aMS-ARC depicting ESR1-RIME data conducted on SUM44-LTED (ESR1Y537S) vs.
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target genes, PGR, TFF1, GREB1, and CTSD (Supplementary
Fig. 10f, g). Taken together, these data show that the ESR1Y537C
mutation is paramount for the ligand-independent phenotype of
MCF7-LTEDY537C cells.
ESR1 mutations show altered responses to endocrine therapy.
One of the most clinically pressing questions relates to the
sensitivity of ESR1 mutations to endocrine therapy. Cell lines
were treated with escalating concentrations of 4-hydroxy-
tamoxifen (4-OHT) or fulvestrant in the presence or absence of
estrogen (Fig. 6a–c; Supplementary Fig. 8). In the absence of
estrogen, both wt-MCF7 and wt-SUM44 showed little sensitivity
to fulvestrant, as expected. SUM44-LTED and both MCF7-LTED
derivatives were sensitive to fulvestrant in the absence of estrogen
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conﬁrming ESR1 ligand independence, irrespective of mutation
state. In the presence of estrogen, sensitivity to both 4-OHT and
fulvestrant was reduced in the low concentration range in
SUM44-LTED compared to wt-SUM44. However, while
ESR1Y537S was not inhibited by 4-OHT, it was by fulvestrant. Wt-
MCF7, MCF7-LTEDY537C, and MCF7-LTEDwt all showed similar
sensitivity to 4-OHT. However, MCF7-LTEDY537C in the pre-
sence or absence of estrogen showed greater sensitivity to ful-
vestrant compared to MCF7-LTEDwt. The sensitivity of the
MCF7-LTEDY537C model to the antiproliferative effect of ful-
vestrant was further supported in vivo (Fig. 6d).
We subsequently assessed response to drugs inhibiting path-
ways associated with endocrine resistance such as mTORC
(RAD001), ERK1/2 (U0126), and ERBB2/EGFR (lapatinib)2.
SUM44 derivatives were resistant to the antiproliferative effects of
lapatinib and U0126 and showed similar sensitivity to RAD001.
The MCF7 derivatives revealed limited response to lapatinib.
MCF7-LTEDY537C and wt-MCF7 showed a similar response to
RAD001 but not U0126, where MCF7-LTEDY537C showed
marked sensitivity in keeping with the increased levels of
pERK1/2 in this cell line. The MCF7-LTEDwt showed little
antiproliferative response to any of the agents tested, suggesting
this cell line has a high degree of kinase plasticity (Supplementary
Fig. 11a, b).
Discussion
Acquired resistance to endocrine therapy is a major clinical
problem and the elucidations of pathways associated with relapse
are of paramount clinical importance to facilitate improvement in
treatment. While somatic mutations in ANDR have been strongly
linked with lack of response to hormone therapy and/or agonist
response to anti-androgens in prostate cancer, it is only recently
that the importance of ESR1 mutations in BC has been reported
(reviewed by Jeselsohn et al.7). In vitro studies using ectopic
expression cassettes suggest that the most commonly found
mutations, Y537S and D538G, confer ligand independence and
exhibit reduced sensitivity to tamoxifen and fulvestrant11,12.
We describe for the ﬁrst time the identiﬁcation of naturally
occurring ESR1 mutations in ESR1-positive BC cell lines.
Importantly, we show that estrogen depletion selects for cells
harboring ESR1 mutations, resulting in estrogen-independent
growth and expression of the ESR1 transcriptome. We believe
that normal culturing of BC cell lines in the presence of estrogen
obviates the need for ESR1 mutations and that only with the
strong selective pressure imparted by culturing in estrogen-
depleted medium are alternative growth pathways, including
ESR1 mutations enriched. Furthermore, estrogen deprivation
appears to be the primary point for enrichment, as ESR1 mutated
cells did not appear to be augmented during acquisition of
resistance to tamoxifen or fulvestrant in vitro. This observation is
analogous to our recent clinical study in which ESR1 mutations in
ctDNA of metastatic BC patients were found almost exclusively in
patients that had become resistant to AI treatment10,13.
Additionally, treatment with fulvestrant in vitro appeared to
enrich for the pre-existing Y537C mutation (MCF7-LTED-ICIR).
ChIP-seq analysis suggested that ESR1Y537S functions in a
ligand-independent manner, largely recapitulating the estrogen-
bound-ESR1wt cistrome, which was demonstrated by the fact that
ER binding sites and their genomic distribution was over-
whelmingly similar in wt-SUM44 and SUM44-LTED cells. The
Y537S mutation lies near helix 12 (H12), which governs the
ligand-regulated actions of ESR1 via AF-2. Recent studies have
suggested that Y537S enables H12 to undergo a conformational
change exposing the AF-2 cleft, facilitating recruitment of cor-
egulators in the absence of hormone, leading to further stabili-
zation of H12. In the same study, it was shown that Y537S also
increased afﬁnity for AIB125. Assessment of the ESR1Y537S
interactome using RIME showed no increase in the association of
the naturally occurring mutant ESR1 with AIB1, but did show
increased association with FOXA1 and GREB1. One possible
explanation for this difference is that the structural studies ana-
lyzed only the ESR1 LBD and nuclear receptor interacting
domain of AIB125 and thus cellular context was not explored.
Despite this compelling data, indicating the mutant ESR1 is
sufﬁcient to drive adaptation to estrogen deprivation, the cell
lines, similar to clinical samples, are heterozygote for both wt and
ESR1 mutant alleles. As such, we cannot conclusively differentiate
between binding events due to wt and mutant ESR1, so it is
possible that the wt allele predominates in LTED. However, there
is no evidence in clinical samples that all ESR1 alleles are mutated
in metastatic BC cases11,12,26–29. Moreover, MCF7Y537S cells,
generated by CRISPR-Cas9-mediated knockin mutagenesis,
which are heterozygote for ESR1Y537S and express both wt and
Y537S mutant ESR1, show estrogen-independent recruitment of
ESR1 and coactivators to ESR1 binding regions24. These cells
demonstrate estrogen-independent expression of ESR1 target
genes and grow in an estrogen-independent manner, validating
the contribution of the Y537S mutation to estrogen independence
when co-expressed with ESR1wt.
A second caveat is the role of altered kinase signaling pathways
that may arise from extended growth in estrogen-depleted culture
conditions to generate LTED and post-translational changes that
may impact on the resistance phenotype. Our own studies and
those of others have shown that altered kinase signaling can lead
to ligand-independent activation of ESR1 (reviewed by Ma
et al.2). Furthermore, ectopic expression of AKT has been shown
to alter the genome-wide binding pattern of ESR130 and that EGF
induces a transcriptional program distinct from estrogen31.
However, genomic proﬁling of SUM44-LTED cells harboring
ESR1Y537S did not provide evidence for altered ESR1 binding
patterns compared to wt-SUM44. Second, the CRISPR-Cas9-
derived MCF7Y537S cells showed estrogen independence in the
absence of prolonged culturing in estrogen-depleted conditions.
Finally, CRISPR-Cas9 editing of the Y537C allele re-established
estrogen dependence in MCF7-LTEDΔ537C cells, demonstrating a
requirement for the Y537C mutation for the estrogen
Fig. 4 Characterization of CRISPR-cas9-modiﬁed wt-MCF7 expressing ESR1Y537S. a Viability assay showing MCF7Y537S proliferates in the absence of
exogenous E compared to wt-MCF7 (n= 6 technical replicates and three biological replicates). Mean growth at day12± SEM relative to day 0. b
Immunoblotting showing alterations in the expression of ESR1, PGR, CTSD, TFF1, and RARA. c Overlap between wt-MCF7 and MCF7Y537S ESR1 binding
sites in the absence of E and d corresponding heatmap. The heatmap depicts binding peak intensities that are common or different between the wt-MCF7
and MCF7Y537S. The window represents ±5 kb regions from the center of the binding event. e Comparison of the average read count between wt-MCF7
and MCF7Y537S in the absence of E showing peak afﬁnity in both cell lines (left) and those binding sites only signiﬁcant in MCF7Y537S (right) (q-value<
0.05). f Bar chart showing the genomic distribution of ESR1 binding sites across the genome in both cell lines. g Volcano plot showing changes in gene
expression by RNA-seq as a result of differential ESR1Y537S binding in MCF7Y537S showing increased expression of estrogen-regulated and proliferation-
associated genes. h Venn-diagrams showing intersect between wt-MCF7 and CRISPR generated MCF7Y537S ChIP-seq peaks in response to ethanol
(ETOH) or estradiol (E) and intersect between SUM44-LTED and MCF7Y537S in the absence of E
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independence. Taken together, our results support the notion that
activating mutations in the ESR1 are sufﬁcient for driving
acquired resistance that does not necessitate changes in other
signaling pathways.
Moreover, our in vitro data indicate that ESR1Y537S/C muta-
tions are responsive to fulvestrant, as ESR1 protein expression
was downregulated (Fig. 6c), although suppression of growth was
less pronounced at low concentrations of the drug, indicating
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partial resistance of ESR1Y537S but not ESR1Y537C. Nonetheless,
at the predicted clinically achievable concentrations of fulves-
trant32,33, ESR1Y537S was as equally sensitive as the ESR1wt. This
is in keeping with our previous clinical data, which suggests
patients harboring an ESR1 mutation show longer progression-
free survival when treated with fulvestrant vs. exemestane13.
However, in contrast to Y537C, Y537S showed reduced sensitivity
to 4-OHT. One explanation for these observations is that, 4-OHT
causes Y537S to stabilize H12 by the formation of a hydrogen
bond between 537S and E380, effectively reducing the potency of
the drug. In contrast, binding of fulvestrant disorders H12. As
such, some of the new SERM/SERD agents with enhanced
pharmacokinetics capable of increasing the dynamics of H12 may
show increased potency against this mutation25.
Interestingly, MCF7-LTEDwt show evidence of reduced ESR1
activity, with lower expression of estrogen-regulated genes such as
PGR and increased expression of genes associated with anti-
apoptotic activity34. Unexpectedly, LTED cells expressing ESR1wt
were also less sensitive to fulvestrant compared to ESR1Y537C.
One explanation is that these cells already have elevated kinase
activities and are thus less dependent on ESR1, highlighting once
again the complexity of cellular context as well as mutation status
on response to endocrine therapy.
Recent genetic studies that have identiﬁed ESR1 mutations in
metastatic, endocrine-resistant BC indicate that these mutations
result from the selective pressure imposed by inhibition of ESR1
activity by hormonal therapies. The results presented here pro-
vide support for this hypothesis. The independent BC cell line
models identiﬁed here also provide an important resource for
studying the relative contribution of ESR1 mutations and
alterations in other signaling pathways, that lead to endocrine
resistance. Indeed, the genomic studies described herein provide
support for the importance of kinase signaling cascades that have
already been implicated in endocrine resistance by our studies, as
well as those of other investigators. Our ﬁndings demonstrate that
ESR1 mutations provide an important, albeit not the only driver
of acquired endocrine resistance, concordant with the clinical
observation that ~20% of metastatic tumors harbor mutant ESR1.
Using resistance models featuring ESR1 mutations and those that
do not involve ESR1 mutations should prove to be valuable in
aiding patient management, and for assessing new treatment
approaches for endocrine-resistant BC. We and others will need
to consider the presence and any phenotypic effects of these and
possibly other acquired/selected mutations when using these
derived cell lines for mechanistic or pharmacological studies and
interpreting data from them.
Methods
Reagents. Following antibodies were used for immunoblotting: pESR1ser167 (CST
cat-5587, 1:1000), pESR1ser118 (CST cat-2511, 1:1000), total-ESR1 (Santa Cruz
sc8002, 1:800 or Novacastra (NCL-ER-6F11), 1:1000), total-FOXA1 (Abcam
Ab23738, 1:1000) total-PGR (Novocastra NCL-L-PGR, 1:500 or Santa Cruz sc-538,
1:200), pERBB2 (CST-2243, 1:1000), total-ERBB2 (CST-4290, 1:1000), pEGFR
(CST-3777, 1:1000), total-EGFR (CST-2232, 1:1000), pAKTser437 (CST-9271,
1:1000), total-AKT (CST-9272, 1:1000), pERK1/2 (Sigma-Aldrich, 1:2000), total-
ERK1/2 (CST-9102, 1:1000), TFF1 (Santa Cruz sc28925, 1:200), RARA (Abcam
Ab39971, 1:1000), cathepsin D (CTSD) (Abcam Ab6313, 1:2000), actin (Abcam
Ab6276, 1:10,000), and tubulin (Sigma T-9026, 1:2000). Secondary antibodies
(horseradish peroxidase-linked, 1:2000) were obtained from Dako. For ChIP, the
following antibodies were used: ESR1 (Santa Cruz sc543), CBP (Santa Cruz sc369),
and FOXA1 (Abcam Ab23738). 17-β-estradiol (E) and 4-hydroxytamoxifen (4-
OHT) were purchased from Sigma-Aldrich and fulvestrant (ICI182780) from
Tocris Bioscience.
Cell culture. Wt-MCF7, wt-HCC1428, wt-ZR75.1, and wt-SUM44 were purchased
from the ATCC and Asterand. Cell lines were banked in multiple aliquots upon
receipt to reduce risk of phenotypic drift and identity conﬁrmed by short tandem
repeats (STR) proﬁling. All cell lines were routinely screened for mycoplasma
contamination. Wt cell lines were cultured in phenol red-free RPMI supplemented
with 10% fetal bovine serum (FBS) and exogenous estradiol (1 nM). The respective
LTED derivatives were cultured, as previously described14,15 in phenol red-free
RPMI supplemented with 10% dextran charcoal stripped FBS (DCC medium). ICI-
R and TAMR cell lines were cultured in their respective basal medium supple-
mented with 100 nM fulvestrant (ICI182780) or 100 nM 4-OHT. All experiments
were performed under basal conditions unless otherwise stated.
Proliferation assays. Proliferation assays were performed as previously described
for experiments involving drugs and siRNA studies14,15. In summary, cells were
deprived of estrogen for 48–72 h prior to treatment with On-target plus siRNA for
human-siFOXA1 or non-targeting pool (sicontrol) (Thermo scientiﬁc, Dharma-
con). Knockdown efﬁcacy was determined by qRT-PCR. For drug studies, cells
were treated for 6 days with a medium change at day 3, as previously described14.
To analyze growth over time, cells were cultured as detailed above in DCC medium
with or without estradiol and data recorded using an IncuCyte ZOOM live cell
analyzer (Essen Biomedics). Three images per well were taken every 12 h over a 6-
day period.
qRT-PCR. RNA was extracted using the RNeasy kit (Qiagen), quantiﬁed and
reverse-transcribed with SuperScriptIII First Strand Synthesis System (Invitrogen).
Taqman gene expression assays (Applied Biosystems) were used to quantify TFF1
(Hs00907239_m1 and Hs00170216_m1), PGR (Hs00172183_m1), GREB1
(Hs00536409_m1), CTSD (Hs00157201_m1), ESR1 (Hs00174860_m1), CCND1
(Hs00765553_m1), and the house-keeping genes FKBP15 (Hs00391480_m1) and
GAPDH (Hs99999905_m1). The relative quantity was determined using ΔΔCt,
according to the manufacturer’s instructions (Applied Biosystems).
Exome sequencing. Exome libraries were generated with SureSelect Human All
Exon V5 kit and sequenced (paired-end 100 bp) on an Illumina HiSeq2500. Reads
were aligned to GRCh37-lite-build37 using BWA mem (v0.7.12-r1039)35, sorted
with samtools (v1.2)36 and further processed using picard tools (http://picard.
sourceforge.net) (v1.128) with default parameters. Single nucleotide variants
(SNVs) were detected using VarScan v2.3.537 with default parameters (except
--mpileup 1, --output-vcf) and wt cell samples as baseline. Multi-mapped reads
were excluded and base alignment quality (BAQ) was turned off for pileup with
samtools. To get high conﬁdence somatic mutations, SNVs were ﬁltered by using:
(i) processSomatic of VarScan with empirically-derived criteria: minimum VAF in
LTED cells: 0.10, maximum VAF in wt: 0.05, p-value = 0.07; (ii) fpﬁlter.pl from
VarScan together with bam-read count (--min-base-quality 15, --min-mapping-
quality 1) to reduce number of false positives. Variants were annotated using
SnpEff v4.1 B (http://snpeff.sourceforge.net/SnpEff_manual.html). Mutations were
annotated with Tier levels38 using BedTools v2.22.139. ascatNGS (https://github.
com/cancerit/ascatNgs) was used to generate LogR and BAF values. Data have been
deposited in the sequence read archive: BioProject ID PRJNA390496.
Ion torrent. DNA was ampliﬁed using Ion AmpliSeq Library Kit 2.0 (Life Tech-
nologies), digested, Ion Xpress.
Barcode adapters ligated and puriﬁed with Agencourt AMPure XP magnetic
beads (Beckman Coulter). Libraries were quantiﬁed by qPCR using an Ion Library
Quantiﬁcation Kit (Life Technologies), templated on the Ion OneTouch2 System
Fig. 5 ESR1wt and ESR1Y537C regulate altered ESR1 cistrome. a Bar chart showing the genomic distribution of ESR1 binding sites across the genome in wt-
MCF7, MCF7-LTEDwt, and MCF7-LTEDY537C showing altered promoter (≤1 kb) and distal intergenic occupancy. b Volcano plots showing changes in gene
expression by RNA-seq in MCF7-LTEDY537C, MCF7-LTEDwt, and wt-MCF7. c Heatmap depicting the changes in gene expression of the four clusters
comparing wt-MCF7 to MCF7-LTEDY537C, wt-MCF7 to MCF7-LTEDwt, and MCF7-LTEDY537C to MCF7-LTEDwt. d Average log2 differences for all genes
within each set for wt-MCF7, MCF7-LTEDwt, and MCF7-LTEDY537C. e Pathway analysis of the four clusters using GSEA. Data were derived from n= 2
biological replicates for ChIP-seq and n= 3 biological replicates for RNA-seq. f Metabolic dependency and capacity of wt-MCF7, MCF7-LTEDwt, and
MCF7-LTEDY537C on glutamine, fatty acid, and glucose using a Seahorse XFe96 analyzer (n= 4 technical replicates). Signiﬁcance was assessed by one-
way ANOVA and Tukey’s test. *p< 0.05, **p< 0.01, ***p< 0.001. g Comparison of the migratory ability of wt-MCF7, MCF7-LTEDwt, and MCF7-
LTEDY537C (n= 8 technical replicates). Data shown are mean± SEM. Signiﬁcance was assessed by Student’s t test. *p< 0.05, **p< 0.01, ***p< 0.001
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(Life Technologies) and sequenced on the Ion PGM System (Life Technologies).
Reads were aligned by the PGM server with standard settings to the reference
genome hg19, samtools v1.2 was used to calculate the on-target coverage.
IonReporter (v4.4) was used for mutation calling (parameters: data quality
stringency = 12, downsample to coverage = 4000, SNP/InDel/MNP min cov each
strand = 50, SNP/InDel/MNP min variant score = 15, SNP/InDel/MNP min
coverage = 250, hotspot min variant score = 6, hotspot min coverage = 150). All
mutations called were manually reviewed in Integrative Genomics Viewer (IGV)
and included in the analysis if they had a VAF ≥ 1%.
ddPCR. ddPCR assays for the ESR1 mutations Y537S and Y537C using Taqman
probes were used as previously described10. Very-low-frequency mutations were
only considered to be present if two or more FAM-positive droplets were detected
in the total of the wt sample.
Cycle sequencing for validation. ESR1 mutations were validated by cycle
sequencing by euroﬁns genomics (Euroﬁns). DNA was ampliﬁed using forward
primer 5ʹ- AAGTGGCTGCAGGGAGAGT-3ʹ and reverse primer 5ʹ-
TGGTGCATGATGAGGGTAAA-3ʹ.
Fluorescence in situ hybridization. FISH probes hybridizing at 6q25 (ESR1) and
chromosome-6 (CEN6) were purchased from Empire Genomics. Cell pellets were
ﬁxed in 4% paraformaldehyde and parafﬁn-embedded. Five-micron sections were
subjected to the SwiftFISH rapid hybridization protocol (Empire Genomics),
according to the manufacturer’s instructions. Sections were mounted in DAPI-
containing Vectashield (Vector). FISH probes signals were analyzed using ﬂuor-
escent microscope (Leica).
RNA-seq. Libraries were created after Ribo-zero rRNA Removal Kit (Illumina)
using NEBNext Ultra Directional RNA (NEB) or Truseq Stranded Total RNA
(Illumina) Library Prep Kit and sequenced using the HiSeq2500 (paired-end 100 bp
v4 chemistry). Tophat (v2.1) and Cuffdiff (v2.2.1)40 using default parameters
(GSE100075). K-means clustering was performed using the k-means function in
the stats package in R. The number of clusters used was determined by the number
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Fig. 6 Antiproliferative effect of endocrine therapy in ESR1 mutant and wt cell lines. a Proliferation assays assessing response of wt-SUM44 and SUM44-
LTED and b wt-MCF7, MCF7-LTEDwt, and MCF7-LTEDY537C to escalating concentration of fulvestrant± E (estradiol) and 4-OHT plus E (estradiol). c
Treatment of wt-SUM44, SUM44-LTEDY537S, wt-MCF7, MCF7-LTEDY537C, and MCF7-LTEDwt with fulvestrant (10 nM) results in loss of ESR1 expression
irrespective of mutation status (n= 3 biological replicates consisting of n= 8 technical replicates). Data represent mean± SEM. d Xenograft models of
MCF7-LTEDY537C in response to vehicle or fulvestrant. Data represent median fold change in tumor volume. Signiﬁcance was assessed using an unpaired t-
test
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of clusters generated in unsupervised clustering using hclust (method = complete)
function in R with of a matrix of correlation-based distances using the Spearman
method.
ChIP-seq. ChIP-qPCR and ChIP-seq were performed, as previously described14,41.
Paired-end 50 bp ChIP-seq data were generated by rapid-mode HiSeq. Reads were
aligned to the Human Reference Genome (assembly hg19) using BWA35 removing
all reads with a quality score< 15. Peaks were called using MACS2
(v2.1.0.20150420)42 with default parameters. Only binding events that occurred in
two biological replicates were considered differential binding sites using Diffbind
v1.14.543 and R v3.2.1. Motif analysis was performed using centrimo (500 bp
centered on summit of peak) (http://meme-suite.org/) (GSE100074). Bar charts
were generated with ChIPseeker package in R44.
GSEA. Integration of RNA-seq and ChIP-seq diffBind data were carried out using
GSEA, as previously described45. In summary, all genes assessed using RNA-seq
were ranked and weighted by their mean Log2 fold change. Lists of genes that
overlapped with regions showing signiﬁcant differential binding were identiﬁed.
These data were then analyzed using the GSEA v2.0.13 GSEA Pre-ranked tool. The
default setting was applied. Finally, additional analysis of gene sets (e.g., overlaps
between signiﬁcant binding events and closest genes that are signiﬁcantly differ-
entially expressed) were performed using the Molecular Signature Database (http://
software.broadinstitute.org/gsea/msigdb/annotate.jsp) to compute overlaps with
Hallmark gene sets that represent well-deﬁned biological states or processes. Sig-
niﬁcance of overlap between gene sets was determined by hypergeometric test.
RIME and dimethyl labeling. RIME22 and stable isotope dimethyl labeling21 were
performed, as previously described. The wt-SUM44 and SUM44-LTED were
labeled with the medium and light isotope reagent, respectively. Labeled samples
were pooled at an approximate 1:1 ratio, dried down and fractionated using 12 cm
IPG strip pH 3–10, as previously described46. RIME and dimethyl label fractions
were desalted (SUM SS18V, The Nest Group Inc) and run through LC-MS/MS
using LTQ Velos Orbitrap MS. The data acquisition mode was set, as previously
described46. Raw data for RIME and dimethyl labeling were analyzed using
MaxQuant 1.5.1.046,47. Search parameters were as previously described46. All
proteomics data are deposited within the PRIDE database (PXD004807).
Identiﬁcation of mutation at protein level using ddMS2/PRM. ESR1-RIME
samples were subjected to ddMS2-PRM analysis in order to verify the presence of
wt and mutated serine or cysteine in the SUM44-LTED and MCF7-LTED samples,
respectively (Supplementary Data 3). The analysis was performed using a Q-
Exactive HF mass spectrometer (Thermo Scientiﬁc, Hemel Hempstead, UK). For
each analysis, three biological replicates with two technical replicates were run.
Heavy peptides were purchased from Thermo Fischer Scientiﬁc (PEPOTEC, grade
3). Reversed phase chromatography was performed on a Dionex UltiMate 3000
RSLC nano system (Thermo Fisher Scientiﬁc, Hemel Hempstead, UK) using an
Acclaim PepMap100 C18 trap cartridge (0.5 mm i.d. × 5 mm, 5 µm bead size, 100 Å
pore size; loaded in a bi-directional manner). Peptides were resolved on a 75 µm I.
D. 50 cm C18 Easy-Spray packed emitter column (2 µm particle size; PepMap
RSLC, Thermo Scientiﬁc, Hemel Hempstead, UK) over 90 min using a three-step
gradient of 96:4 to 50:50 buffer A:B (t = 0 min 4% B, 0.5 min 4% B, 12.0 min 10% B,
43.0 min 25% B, 90.0 min 50% B) (buffer A: 2% acetonitrile/0.1% formic acid;
buffer B: 80% acetonitrile/0.1% formic acid) at 250 nl per min. Peptides were
iodized by electrospray ionization using 1.8 kV applied using the Easy-Spray ion
Source. Sample was infused into the mass spectrometer directly from the packed
emitter (5 µm exit bore). The ion transfer tube was heated to 275 °C and the S-lens
set to 50%. MS/MS were acquired using parallel reaction monitoring (PRM) and
data-dependent (ddMS2) acquisitions based on a full FT-MS scan from 350 to
1850m/z at 120,000 resolution, with a target automatic gain control (AGC) value of
3,000,000 and a maximum injection time of 50 ms. No internal lock mass calibrant
was used. Eight PRM scans were triggered (FT-Orbitrap scans at 30,000 resolution,
AGC target 2e5, 100 ms maximum injection time, normalized collision energy 35)
if an ion from scheduled inclusion list was present. Then, the top ﬁve most intense
ions were fragmented by higher energy collision-induced dissociation and dyna-
mically excluded for 20 s (FT-Orbitrap scans at 30,000 resolution, AGC target 1e5,
activation time 10 ms, 50 ms maximum injection time, normalized collision energy
28, selected ﬁrst mass at 140m/z). Precursor ions with unknown or single charge
states were excluded from selection. Data analysis of raw MS/MS was carried out
using Mascot V2.3 via Proteome Discoverer v1.4. Peak lists were searched against
the human Uniprot FASTA database (20,305 sequences) containing the wt and
mutant sequence. Spectra were searched for a match to fully-tryptic peptides with
up to two missed cleavage sites. Search parameters were chosen as follows: serine/
threonine phosphorylation, protein N-terminal acetylation, peptide N-terminal
glutamine to pyroGlu, and oxidation of methionines were all considered as variable
modiﬁcations, whereas cysteine carbamidomethylation was selected as a ﬁxed
modiﬁcation. Precursor ion mass tolerance was set to 15 ppm for the ﬁrst search,
fragment ion mass tolerance for ion analyzed spectra was set to 0.02 Da. Resulting
peptide and protein lists were grouped and validated using Scaffold v4 (Proteome
Software Inc., Portland, OR). Protein identiﬁcations were automatically accepted if
they contained at least two unique peptides assigned at 1% FDR. The raw data have
been deposited in Passel (PASS01062).
Immunoblotting. Whole-cell extracts were generated from cells cultured under
basal conditions or DCC medium with or without the addition of estrogen for
comparative studies where noted. Equal amounts of protein were resolved by
SDS–PAGE and subjected to immunoblot analysis. Antigen–antibody interactions
were detected with ECL reagent (Amersham, UK) using the antibodies referred
above.
CRISPR-Cas9-mediated generation of the MCF7-LTEDΔ537C cells. Gene
knockins for a modiﬁed ESR1 exon 8, encoding a wt open reading frame with silent
mutations to facilitate PCR analysis, were made using CRISPR-Cas9-mediated
homologous recombination in MCF7-LTEDY537C cells. ESR1 gene targeting was
carried out using CRISPR 4834093 (5ʹ-GAGTGCTGAAATCCCTAGAA-3ʹ) cloned
into a guide-RNA expression plasmid (a gift from George Church; Addgene
plasmid #41824), as described previously24. The target sequence for this CRISPR is
located in intron 7, on the antisense strand, 73 nt from the start of ESR1 Exon 8.
For making the gene knockin, a previously described ESR1 exon 8 Y537S gene
targeting donor construct24 was modiﬁed by site-directed mutagenesis to change
codon 537 from Serine (TCT) to Tyrosine (TAT), as found in the wt sequence.
Additional mutations, to destroy the PAM for CRISPR 4834093, were made by
changing a run of four C nucleotides, located 77 nt 5ʹ to the start of ESR1 Exon 8, to
four G nucleotides. Genome editing, detection of gene targeting events, and
sequence characterization of gene targeted alleles were carried out as described
previously24, with the exception that following transfection, cells were recovered in
full medium supplemented with 10% FCS, and Exon 8 knockin clones identiﬁed
through stochastic cloning.
Energy phenotype and Mito Fuel Flex analysis. SUM44 and MCF7 cells were
plated at a conﬂuency of 1.0 × 104 per well in a 96-well Seahorse cell culture
microplates and incubated in a 5% CO2 incubator at 37 °C overnight. The next
morning, culture media was replaced with pH-adjusted (pH = 7.4± 0.1)
bicarbonate-free DMEM with 10 mM glucose, 1 mM sodium pyruvate, and 2 mM
L-glutamine. The plate was then incubated at 37 °C for 1 h in a non-CO2 incubator.
For the Mito Fuel Flex test, oxygen consumption rates were measured using the
Seahorse XF Mito Fuel Flex Test Kit (Agilent, 103260-100) on an XFe96 Analyzer.
Cell numbers were normalized using CyQuant (Thermo Fisher, C35012).
Cell migration assay. Cells growing in basal media were washed several times with
phenol red-free RPMI1640 containing 1% DCC-FBS. A total of 2.5 × 104 cells were
seeded into the upper chambers of Corning FluoroBlok 96-multiwell insert system
plates (Corning, UK). The lower chambers were ﬁlled with RPMI1640 containing
1% DCC-FBS plus 100 ng/ml human recombinant EGF, as chemo-attractant, and
plates were incubated at 37 °C. After 16 h, the medium was removed from the
lower chambers and wells were washed with PBS. PBS containing 1 μM calcein
AM (Invitrogen) was added to the lower chambers and the plates were incubated at
37 °C for 30 min. Fluorescence intensity was measured from the bottom of the
plates using a 490 nm excitation ﬁlter and a 520 nm emission ﬁlter in a Victor X5
plate reader (PerkinElmer). Data are expressed as the mean of eight technical
replicates.
Human tumor xenografts modeling relapse on AI therapy. In vivo studies were
carried out in ovariectomized 8- to 12-week-old female BALB/c nude mice in
accordance with Home Ofﬁce Guidelines and approved by the Institute of Cancer
Research Ethics Committee. Xenografts modeling patients resistant to AI were
initiated by innoculating MCF7-LTEDY537C (107) cells in basement membrane
matrix (Matrigel; BD Biosciences) into the right ﬂank of each animal. Once
tumors reached 7 mm in size, they were size matched and mice treated with either
5 mg per kg fulvestrant once per week or vehicle control. The study operator was
blinded to treatment. Tumor growth was assessed twice weekly in both arms by
caliper measurements of the two largest diameters. Volumes were then calculated
according to the formula: a × b2 × π/6, where a and b are orthogonal tumor dia-
meters. Tumor volumes were then expressed as median relative fold change in
volume at the start of treatment. At the end of study, data were available for seven
animals in the control arm and nine animals in the fulvestrant treatment arm.
Overall statistical differences between the treatment and control arms were cal-
culated using an unpaired t-test.
Statistics analysis. Statistical methodologies pertinent to each method are held
within the sections above.
Data availability. The data supporting the ﬁnding from this manuscript have been
deposited as follows. Whole-exome sequencing has been deposited in the sequence
read archive BioProject ID PRJNA390496. RNA-seq and ChIP-seq data have been
deposited with the NCBI gene expression omnibus (GEO) (http://ncbi.nlm.nih.
gov/geo/): ChIP-seq data for wt-MCF7, MCF7-LTEDwt, MCF7-LTEDY537C wt-
SUM44 and SUM44-LTED (GSE100074), RNA-seq (GSE100075) for wt-MCF7,
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MCF7-LTEDwt, MCF7-LTEDY537C, wt-SUM44 and SUM44-LTED, CRISPR-cas9
MCF7Y537S ChIP-seq and RNA-seq data (GSE78286)24. All proteomics data sets
are deposited within the PRIDE database (PXD004807) or Passel (PASS01062) for
targeted sequencing.
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